309 related articles for article (PubMed ID: 17661720)
41. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
42. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
43. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
44. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era.
Bianco FJ
Urol Oncol; 2008; 26(4):408-14. PubMed ID: 18593619
[TBL] [Abstract][Full Text] [Related]
45. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
Stephan C; Schnorr D; Loening SA; Jung K
Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
[No Abstract] [Full Text] [Related]
46. Medical technologies for the diagnosis of prostate cancer.
Fitzsimons NJ; Sun L; Moul JW
Expert Rev Med Devices; 2007 Mar; 4(2):227-39. PubMed ID: 17359227
[TBL] [Abstract][Full Text] [Related]
47. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
48. Are multiple markers the future of prostate cancer diagnostics?
Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
[TBL] [Abstract][Full Text] [Related]
49. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
Shariat SF; Scherr DS; Gupta A; Bianco FJ; Karakiewicz PI; Zeltser IS; Samadi DB; Akhavan A
Arch Esp Urol; 2011 Oct; 64(8):681-94. PubMed ID: 22052751
[TBL] [Abstract][Full Text] [Related]
50. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
51. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
52. Prostate cancer in the elderly.
Heinzer H; Steuber T
Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
[TBL] [Abstract][Full Text] [Related]
53. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
54. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.
Bratslavsky G; Fisher HA; Kaufman RP; Voskoboynik D; Nazeer T; Mian BM
Urol Oncol; 2008; 26(2):166-70. PubMed ID: 18312936
[TBL] [Abstract][Full Text] [Related]
55. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
56. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
Bellera CA; Hanley JA; Joseph L; Albertsen PC
Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors.
Kim JP; Lee BY; Lee J; Hong S; Sim SJ
Biosens Bioelectron; 2009 Jul; 24(11):3372-8. PubMed ID: 19481922
[TBL] [Abstract][Full Text] [Related]
58. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM
J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534
[TBL] [Abstract][Full Text] [Related]
59. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
Watson AP; Egland KA
S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
[TBL] [Abstract][Full Text] [Related]
60. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
